Therapy-related acute myelogenous leukemia and myelodysplastic syndrome

Borthakur, G.; Estey, A.E.E.

Current Oncology Reports 9(5): 373-377

2007


ISSN/ISBN: 1523-3790
PMID: 17706165
DOI: 10.1007/s11912-007-0050-z
Accession: 056551610

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome (t-AML/MDS) are increasing in prevalence with aging of the population and improved survival of patients treated with chemotherapy or radiotherapy for other malignancies. Research focused on the pathogenesis of t-AML/MDS will provide insight into the pathogenesis of de novo AML/MDS. Participation in clinical trials should be encouraged for this patient population because results with available treatment options are clearly suboptimal.

Therapy-related acute myelogenous leukemia and myelodysplastic syndrome